Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BACTRIM vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BACTRIM (sulfamethoxazole/trimethoprim) inhibits bacterial folate synthesis. Sulfamethoxazole, a sulfonamide, inhibits dihydropteroate synthase, blocking PABA incorporation into dihydrofolic acid. Trimethoprim inhibits dihydrofolate reductase, blocking conversion of dihydrofolic acid to tetrahydrofolic acid. Sequential blockade leads to bactericidal effect.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Urinary tract infections,Acute otitis media,Acute exacerbations of chronic bronchitis,Traveler's diarrhea,Shigellosis,Pneumocystis jirovecii pneumonia (treatment and prophylaxis),Toxoplasmosis (prophylaxis in immunocompromised),Nocardia infections,Methicillin-resistant Staphylococcus aureus (MRSA) infections (off-label)
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
1 DS tablet (160 mg TMP/800 mg SMX) orally every 12 hours for 10-14 days.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Sulfamethoxazole: 9-12 hours (prolonged in renal impairment); Trimethoprim: 8-10 hours (prolonged in renal impairment).
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Sulfamethoxazole is metabolized primarily via N-acetylation in the liver (N-acetyltransferase-2, NAT2). Trimethoprim is metabolized via O-demethylation and alpha-hydroxylation by cytochrome P450 (CYP) enzymes, mainly CYP3A4, with minor contribution from CYP1A2 and CYP2C9.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Renal: sulfamethoxazole 20-30% unchanged, trimethoprim 40-70% unchanged; biliary/fecal: minimal (<10%) for both components.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Sulfamethoxazole: 70% bound to albumin; Trimethoprim: 30-40% bound to albumin.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Sulfamethoxazole: 0.21 L/kg; Trimethoprim: 1.8 L/kg (high tissue penetration including lung, kidney, and CSF).
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: 100% for both components (well absorbed).
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Cr Cl >30 m L/min: No adjustment. Cr Cl 15-30 m L/min: 50% of standard dose. Cr Cl <15 m L/min: Contraindicated.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution, monitor for toxicity; consider dose reduction. Child-Pugh Class C: Avoid use.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
8 mg/kg/day TMP / 40 mg/kg/day SMX in two divided doses every 12 hours (max 320 mg TMP/1600 mg SMX per day). For PCP treatment: 15-20 mg/kg/day TMP / 75-100 mg/kg/day SMX in 3-4 divided doses.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Initiate at lower doses; monitor renal function closely; contraindicated if Cr Cl <15 m L/min; adjust based on Cr Cl (see renal adjustment).
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
BACTRIM may cause life-threatening severe adverse reactions including: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Discontinue at first sign of skin rash or any sign of adverse reaction. Hypersensitivity reactions can occur even with re-challenge of the same or other sulfonamides.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Fatal hypersensitivity reactions including SJS/TEN,Hepatotoxicity and hepatic failure,Blood dyscrasias (leukopenia, thrombocytopenia, agranulocytosis),Clostridioides difficile-associated diarrhea,Renal impairment: risk of crystalluria; maintain adequate fluid intake,Hyperkalemia in patients with renal disease or on potassium-sparing drugs,Megaloblastic anemia in folate-deficient patients,Elderly patients at increased risk of severe adverse reactions,Pregnancy: avoid near term due to risk of kernicterus (sulfonamide displaces bilirubin),Lactation: caution; sulfonamides excreted in breast milk,Photosensitivity
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to sulfonamides, trimethoprim, or any component,History of drug-induced immune thrombocytopenia with sulfonamides or trimethoprim,Megaloblastic anemia due to folate deficiency,Severe hepatic or renal impairment (Cr Cl <15 m L/min),Pregnancy at term and during breastfeeding,Infants less than 2 months of age,Combination with dofetilide (increased risk of torsades de pointes)
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid high-potassium foods (bananas, oranges, potatoes) if hyperkalemia is a concern. No specific food interactions; however, maintain adequate fluid intake to prevent crystalluria.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Pregnancy Category D. First trimester: Folate antagonist; associated with neural tube defects, cardiovascular malformations, and cleft palate. Second and third trimesters: Risk of kernicterus in neonates due to displacement of bilirubin from albumin; may cause hemolytic anemia in G6PD-deficient fetuses. Avoid use, especially near term.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Both trimethoprim and sulfamethoxazole are excreted into breast milk. M/P ratio not well defined. Potential for kernicterus in jaundiced or G6PD-deficient infants; may interfere with folate metabolism. Caution advised; consider alternative therapy.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Trimethoprim-sulfamethoxazole dose generally unchanged but avoid in first trimester and near term. If unavoidable, consider increased folate supplementation. No specific pharmacokinetic-driven dose adjustment established; monitor clinical response and adjust based on renal function.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Bactrim is contraindicated in G6PD deficiency due to risk of hemolytic anemia. Monitor renal function and potassium levels, especially in elderly patients, as sulfamethoxazole can cause hyperkalemia. Use with caution in patients with folic acid deficiency or megaloblastic anemia. Avoid in pregnancy at term and in lactating women due to risk of kernicterus. For PCP treatment, high doses may require leucovorin rescue to prevent bone marrow suppression.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take with a full glass of water and stay well-hydrated to prevent crystalluria.,Complete the full course even if symptoms improve.,Report any signs of allergic reaction (rash, fever, sore throat) or severe skin reactions (blistering, peeling).,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Do not take if you have a history of sulfa allergy or are pregnant/nursing without consulting doctor.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BACTRIM vs ALFENTA, answered by our medical review team.
BACTRIM is a Sulfonamide Antibiotic Combination that works by BACTRIM (sulfamethoxazole/trimethoprim) inhibits bacterial folate synthesis. Sulfamethoxazole, a sulfonamide, inhibits dihydropteroate synthase, blocking PABA incorporation into dihydrofolic acid. Trimethoprim inhibits dihydrofolate reductase, blocking conversion of dihydrofolic acid to tetrahydrofolic acid. Sequential blockade leads to bactericidal effect.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BACTRIM and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BACTRIM is: 1 DS tablet (160 mg TMP/800 mg SMX) orally every 12 hours for 10-14 days.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BACTRIM and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BACTRIM is classified as Category C. Pregnancy Category D. First trimester: Folate antagonist; associated with neural tube defects, cardiovascular malformations, and cleft palate. Second and third trimesters: Risk of . ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.